Literature DB >> 20455612

Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth.

Elaine F Walker1, Patricia A Brennan, Michelle Esterberg, Joy Brasfield, Brad Pearce, Michael T Compton.   

Abstract

Elevations in hypothalamic-pituitary-adrenal (HPA) axis activity have been implicated in the origins and exacerbation of mental disorders. Several lines of investigation suggest HPA activity, indexed by increased cortisol, is elevated in patients with schizophrenia and other psychotic disorders. This study examined the relation of cortisol levels and longitudinal changes with psychotic outcomes in at-risk adolescents. Participants were 56 adolescents who met risk criteria for psychosis, namely, schizotypal personality disorder (n = 5), prodromal symptom criteria based on the Structured Interview for Prodromal Symptoms (n = 17), or both (n = 34). Of these, 14 subsequently met DSM-IV criteria for an Axis I psychotic disorder (schizophrenia, schizoaffective disorder, or mood disorder with psychotic features). Participants were assessed at baseline and then followed longitudinally. Salivary cortisol was sampled multiple times at initial assessment, interim follow-up, and 1-year follow-up. Area under the curve (AUC) was computed from the repeated cortisol measures. The findings indicate that at-risk subjects who subsequently developed psychosis showed significantly higher cortisol at the first follow-up, a trend at the 1-year follow-up, and a significantly larger AUC when compared to those who did not convert. A similar pattern of group differences emerged from analyses excluding those who may have converted prior to the 1-year follow-up. These findings converge with previous reports on HPA activity in psychosis, as well as theoretical assumptions concerning the effects of cortisol elevations on brain systems involved in psychotic symptoms. Future research with larger samples is needed to confirm and extend these results.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20455612      PMCID: PMC3052257          DOI: 10.1037/a0018399

Source DB:  PubMed          Journal:  J Abnorm Psychol        ISSN: 0021-843X


  37 in total

1.  Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability.

Authors:  Tandy J Miller; Thomas H McGlashan; Joanna L Rosen; Kristen Cadenhead; Tyrone Cannon; Joseph Ventura; William McFarlane; Diana O Perkins; Godfrey D Pearlson; Scott W Woods
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

Review 2.  Prospective investigations of the prodromal state of schizophrenia: review of studies.

Authors:  K A Olsen; B Rosenbaum
Journal:  Acta Psychiatr Scand       Date:  2006-04       Impact factor: 6.392

3.  Multiple imputation of discrete and continuous data by fully conditional specification.

Authors:  Stef van Buuren
Journal:  Stat Methods Med Res       Date:  2007-06       Impact factor: 3.021

4.  Reduction in salivary cortisol concentration correlates with resolution of psychosis in Cushing's syndrome.

Authors:  Paul C Myhill; Brett A Sillars; Sergio Starkstein; Tibor Annus; Bu B Yeap
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2008       Impact factor: 2.198

5.  Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients.

Authors:  J P Lindenmayer; M Vital-Herne; N Bark; S Grochowski; N Moynihan
Journal:  Biol Psychiatry       Date:  1997-07-01       Impact factor: 13.382

6.  Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.

Authors:  Peter Gallagher; Stuart Watson; Margaret S Smith; Ian Nicol Ferrier; Allan H Young
Journal:  Biol Psychiatry       Date:  2005-01-15       Impact factor: 13.382

7.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

8.  Diagnosing schizophrenia in the initial prodromal phase.

Authors:  J Klosterkötter; M Hellmich; E M Steinmeyer; F Schultze-Lutter
Journal:  Arch Gen Psychiatry       Date:  2001-02

9.  Comorbid depressive symptoms in the developmental course of adolescent-onset psychosis.

Authors:  Marina Myles-Worsley; Starla Weaver; Francisca Blailes
Journal:  Early Interv Psychiatry       Date:  2007-08-15       Impact factor: 2.732

10.  Positive and negative affect in depression: influence of sex and puberty.

Authors:  Erika E Forbes; Douglas E Williamson; Neal D Ryan; Ronald E Dahl
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

View more
  40 in total

Review 1.  The development of psychotic disorders in adolescence: a potential role for hormones.

Authors:  Hanan D Trotman; Carrie W Holtzman; Arthur T Ryan; Daniel I Shapiro; Allison N MacDonald; Sandra M Goulding; Joy L Brasfield; Elaine F Walker
Journal:  Horm Behav       Date:  2013-07       Impact factor: 3.587

2.  Effects of early trauma on psychosis development in clinical high-risk individuals and stability of trauma assessment across studies: a review.

Authors:  Samantha L Redman; Cheryl M Corcoran; David Kimhy; Dolores Malaspina
Journal:  Arch Psychol (Chic)       Date:  2017-12-18

Review 3.  Stress and neurodevelopmental processes in the emergence of psychosis.

Authors:  C W Holtzman; H D Trotman; S M Goulding; A T Ryan; A N Macdonald; D I Shapiro; J L Brasfield; E F Walker
Journal:  Neuroscience       Date:  2013-01-05       Impact factor: 3.590

Review 4.  The prodrome and clinical risk for psychotic disorders.

Authors:  Sandra M Goulding; Carrie W Holtzman; Hanan D Trotman; Arthur T Ryan; Allison N Macdonald; Daniel I Shapiro; Joy L Brasfield; Elaine F Walker
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2013-06-18

5.  Biomarkers and clinical staging in psychiatry.

Authors:  Patrick McGorry; Matcheri Keshavan; Sherilyn Goldstone; Paul Amminger; Kelly Allott; Michael Berk; Suzie Lavoie; Christos Pantelis; Alison Yung; Stephen Wood; Ian Hickie
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

Review 6.  Biomarkers in psychosis: an approach to early identification and individualized treatment.

Authors:  Heline Mirzakhanian; Fiza Singh; Kristin S Cadenhead
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

Review 7.  Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians.

Authors:  Kristen A Woodberry; Daniel I Shapiro; Caitlin Bryant; Larry J Seidman
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

8.  Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia.

Authors:  Yijuan Du; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

9.  Hypothalamic-pituitary-adrenal axis dysfunction in non-clinical psychosis.

Authors:  Vijay Anand Mittal; Joseph Michael Orr; Andrea Pelletier; Derek James Dean; Ashley Smith; Jessica Lunsford-Avery
Journal:  Psychiatry Res       Date:  2013-01-16       Impact factor: 3.222

10.  Sexual dimorphisms and prediction of conversion in the NAPLS psychosis prodrome.

Authors:  Deborah J Walder; Carrie W Holtzman; Jean Addington; Kristin Cadenhead; Ming Tsuang; Barbara Cornblatt; Tyrone D Cannon; Thomas H McGlashan; Scott W Woods; Diana O Perkins; Larry J Seidman; Robert Heinssen; Elaine F Walker
Journal:  Schizophr Res       Date:  2013-01-20       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.